pixantrone (BBR 2778)

an immunosuppressant; structure given in first source

Also Known As:

BBR 2778; 5,8-bis((2-aminoethyl)amino)-2-aza-anthracene-9,10-dione; 5,8-bis(2-aminoethylamino)-2-azaanthracene-9,10-dione; 6,9-AEA-BIQDO; 6,9-bis((2-aminoethyl)amino)benzo(g)isoquinoline-5,10-dione; BBR-2778; BBR2778

Networked: 83 relevant articles (11 outcomes, 29 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- Fused-Ring Heterocyclic Compounds
  - 2-Ring Heterocyclic Compounds
    - Isoquinolines: 34
      - pixantrone: 83

Experts

1.	Pettengell, Ruth: 9 articles (01/2020 - 11/2009)
2.	Singer, Jack W: 8 articles (01/2020 - 04/2011)
3.	Zinzani, Pier Luigi: 7 articles (01/2021 - 09/2006)
4.	Cutts, Suzanne M: 4 articles (01/2022 - 10/2009)
5.	Phillips, Don R: 4 articles (01/2022 - 10/2009)
6.	Minotti, Giorgio: 4 articles (01/2018 - 02/2013)
7.	Borchmann, Peter: 4 articles (04/2011 - 05/2003)
8.	Bernareggi, A: 4 articles (02/2007 - 12/2000)
9.	Evison, Benny J: 3 articles (01/2022 - 10/2009)
10.	Bregni, Marco: 3 articles (01/2021 - 01/2017)

Related Diseases

1.	Non-Hodgkin Lymphoma (Lymphosarcoma) 06/01/2018 - "Long-Term Response and Remission with Pixantrone in Patients with Relapsed or Refractory Aggressive Non-Hodgkin Lymphoma: Post-Hoc Analysis of the Multicenter, Open-Label, Randomized PIX301 Trial." 09/01/2016 - "This post hoc analysis of a phase 3 trial explored the effect of pixantrone in patients (50 pixantrone, 47 comparator) with relapsed or refractory aggressive B-cell non-Hodgkin lymphoma (NHL) confirmed by centralized histological review. " 09/01/2016 - "Monotherapy with pixantrone in histologically confirmed relapsed or refractory aggressive B-cell non-Hodgkin lymphoma: post-hoc analyses from a phase III trial." 11/01/2009 - "The PIX301 phase III single-agent trial of pixantrone for patients with relapsed or refractory aggressive non-Hodgkin's lymphoma randomized patients to receive either pixantrone or another single agent of the investigators' choice. " 09/01/2006 - "EXTEND PIX301: a phase III randomized trial of pixantrone versus other chemotherapeutic agents as third-line monotherapy in patients with relapsed, aggressive non-Hodgkin's lymphoma."
2.	Diffuse Large B-Cell Lymphoma (Lymphoma, Large Cell, Diffuse) 03/01/2020 - "Limited efficacy of pixantrone in refractory diffuse large B-cell lymphoma." 01/01/2016 - "Results of a multicentre UK-wide retrospective study evaluating the efficacy of pixantrone in relapsed, refractory diffuse large B cell lymphoma." 01/01/2019 - "Patients' decision-making, experiences and preferences regarding pixantrone treatment in relapsed or refractory diffuse large B-cell lymphoma: study protocol for a longitudinal mixed methods study." 08/01/2023 - "Long-term efficacy in patients with relapsed/refractory diffuse large B-cell lymphoma achieving a complete response with pixantrone." 01/01/2021 - "Effectiveness and Safety of Pixantrone for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma in Every-Day Clinical Practice: The Italian Cohort of the PIXA Registry."
3.	Lymphoma (Lymphomas) 01/01/2021 - "However, recent trials (Phase III and real-world studies) reported unsatisfactory results, thereby raising the question about the role of pixantrone in the current treatment of R/R aggressive lymphomas. " 10/01/2007 - "A number of randomised studies of pixantrone (BBR-2778) in patients with relapsed indolent or aggressive lymphomas are ongoing." 01/01/2019 - "In vitro demonstration of synergism with pixantrone combined with targeted agents in lymphomas." 07/01/2012 - "Pixantrone: a new agent for relapsed aggressive lymphomas." 05/01/2009 - "In relapsed aggressive non-Hodgkin lymphomas, weekly single-agent pixantrone 85 mg/m(2) for 3 weeks every 4 weeks was associated with a 27% overall response rate and a 15% complete response rate. "
4.	Neoplasms (Cancer) 01/01/2001 - "This Phase I dose escalation trial of BBR 2778 was conducted to determine the maximum tolerated dose, the dose-limiting toxicity, and the pharmacokinetic profile of BBR 2778 in patients with advanced solid tumors. " 10/11/2023 - "HOIL-1 inhibitors were screened using Autodock Vina, and the anti-tumor effects of pixantrone were evaluated. " 01/01/2022 - "These findings reveal a convergence between KRAS signaling, pixantrone treatment, and radiation conferring tumor cell death." 01/01/2022 - "Pixantrone confers radiosensitization in KRAS mutated cancer cells by suppression of radiation-induced prosurvival pathways." 05/01/2014 - "In vivo pixantrone induced significant differences in EFS distribution compared to controls in two of eight solid tumor xenografts at dose levels relevant to human drug exposure. "
5.	Cardiotoxicity 12/01/2016 - "Despite a low rate of cardiotoxicity of pixantrone reported in clinical trials, the panel recommended that all patients receiving pixantrone should undergo periodical cardiac monitoring." 02/01/2016 - "Three factors potentially contribute to the reduced cardiotoxicity of pixantrone. " 04/01/2015 - "This article provides an overview of treatment-related cardiac toxicity in NHL, the pharmacology of Pixantrone and the evidence supporting its use in NHL. " 07/01/2014 - "Pixantrone showed minimal cardiotoxicity in males and negligible in females at PND 96. " 01/01/2021 - "This article summarizes the definition, structure, mechanism of action and reduced cardiotoxicity of pixantrone as well as efficacy and toxicity both in monotherapy and in combinations, as treatment for aggressive and indolent non-Hodgkin lymphomas."

Related Drugs and Biologics

1.	pixantrone (BBR 2778)
2.	Rituximab (Mabthera)
3.	Mitoxantrone (Novantrone)
4.	Gemcitabine
5.	Anthracyclines
6.	N-Acetylneuraminic Acid (Sialic Acid)
7.	Liposomes (Liposome)
8.	stearylamine
9.	Elements
10.	Sorafenib (BAY 43-9006)

Related Therapies and Procedures

1.	Drug Therapy (Chemotherapy)
2.	Stem Cell Transplantation
3.	Therapeutics
4.	Salvage Therapy
5.	ESHAP regimen